

# Françoise Picarel-Blanchot

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1548370/publications.pdf>

Version: 2024-02-01

7  
papers

521  
citations

1477746

6  
h-index

1719596

7  
g-index

7  
all docs

7  
docs citations

7  
times ranked

397  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Agomelatine 25â€“50Âmg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies. <i>Advances in Therapy</i> , 2021, 38, 1567-1583.	1.3	11
2	Agomelatine in Standard Medical Practice in Depressed Patients: Results of a 1-Year Multicentre Observational Study In France. <i>Clinical Drug Investigation</i> , 2020, 40, 1009-1020.	1.1	12
3	Relative shortâ€term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder. <i>Human Psychopharmacology</i> , 2018, 33, e2646.	0.7	2
4	Sustained efficacy of agomelatine 10 mg, 25 mg, and 25â€“50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months. <i>European Neuropsychopharmacology</i> , 2016, 26, 378-389.	0.3	36
5	Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. <i>Human Psychopharmacology</i> , 2013, 28, 151-159.	0.7	207
6	A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline. <i>CNS Spectrums</i> , 2013, 18, 163-170.	0.7	35
7	Efficacy of the Novel Antidepressant Agomelatine on the Circadian Rest-Activity Cycle and Depressive and Anxiety Symptoms in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 109-120.	1.1	218